Celiac Disease 1 (CELIAC1)

Categories: Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Celiac Disease 1

MalaCards integrated aliases for Celiac Disease 1:

Name: Celiac Disease 1 57 37
Celiac Disease 57 12 25 20 43 36 29 54 42 44 15 17 70
Coeliac Disease 12 73 20 15 32
Celiac Sprue 12 73 25 20 43
Celiac Disease, Susceptibility to 57 29 13
Gluten-Sensitive Enteropathy 25 20
Nontropical Sprue 25 20
Sprue 43 70
Gluten-Sensitive Enteropathy, Susceptibility to, 1 57
Celiac Disease, Susceptibility to, Type 1 39
Celiac Disease, Susceptibility to, 1 57
Celiac Sprue, Susceptibility to, 1 57
Gluten-Sensitive Enteropathy 1 57
Gluten-Induced Enteropathy 20
Childhood Celiac Disease 70
Idiopathic Steatorrhea 12
Gluten Intolerance 20
Gluten Enteropathy 43
Celiac Sprue 1 57
Cœliac Disease 25
Celiac1 57



57 (Updated 20-May-2021)
autosomal recessive

genetic heterogeneity
precipitating factors - ingestion of wheat gluten, rye, and/or barley
presentation in infants - impaired growth, diarrhea, abdominal distention, vomiting
presentation in children - diarrhea, constipation (rarely), short stature, pubertal delay, rickets, iron and folate deficiency with anemia
presentation in adults - episodic or nocturnal diarrhea, flatulence, weight loss, iron deficiency anemia, macrocytic anemia, coagulopathy, vitamin d deficiency


Penetrance The penetrance of celiac disease is low. the risk of developing celiac disease is affected by hla diplotype (see table 2)....


Summaries for Celiac Disease 1

MedlinePlus Genetics : 43 Celiac disease is a condition in which the immune system is abnormally sensitive to gluten, a protein found in wheat, rye, and barley. Celiac disease is an autoimmune disorder; autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. Without a strict, lifelong gluten-free diet, inflammation resulting from immune system overactivity may cause a wide variety of signs and symptoms involving many parts of the body.Celiac disease can develop at any age after an individual starts eating foods containing gluten. The classic symptoms of the condition result from inflammation affecting the gastrointestinal tract. This inflammation damages the villi, which are small, finger-like projections that line the small intestine and provide a greatly increased surface area to absorb nutrients. In celiac disease, the villi become shortened and eventually flatten out. Intestinal damage causes diarrhea and poor absorption of nutrients, which may lead to weight loss. Abdominal pain, swelling (distention), and food intolerances are common in celiac disease. Inflammation associated with celiac disease may lead to an increased risk of developing certain gastrointestinal cancers such as cancers of the small intestine or esophagus.Inflammation and poor nutrient absorption may lead to problems affecting many other organs and systems of the body in affected individuals. These health problems may include iron deficiency that results in a low number of red blood cells (anemia), vitamin deficiencies, low bone mineral density (osteoporosis), itchy skin rashes (dermatitis herpetiformis), defects in the enamel of the teeth, chronic fatigue, joint pain, poor growth, delayed puberty, infertility, or repeated miscarriages. Neurological problems have also been associated with celiac disease; these include migraine headaches, depression, attention-deficit/hyperactivity disorder (ADHD), and recurrent seizures (epilepsy). Many people with celiac disease have one or more of these varied health problems but do not have gastrointestinal symptoms. This form of the condition is called nonclassic celiac disease. Researchers now believe that nonclassic celiac disease is actually more common than the classic form.Celiac disease often goes undiagnosed because many of its signs and symptoms are nonspecific, which means they may occur in many disorders. Most people who have one or more of these nonspecific health problems do not have celiac disease. On average, a diagnosis of celiac disease is not made until 6 to 10 years after symptoms begin.Some people have silent celiac disease, in which they have no symptoms of the disorder. However, people with silent celiac disease do have immune proteins in their blood (antibodies) that are common in celiac disease. They also have inflammatory damage to their small intestine that can be detected with a biopsy.In a small number of cases, celiac disease does not improve with a gluten-free diet and progresses to a condition called refractory sprue. Refractory sprue is characterized by chronic inflammation of the gastrointestinal tract, poor absorption of nutrients, and an increased risk of developing a type of cancer of the immune cells called T-cell lymphoma.

MalaCards based summary : Celiac Disease 1, also known as celiac disease, is related to refractory celiac disease and autoimmune disease, and has symptoms including constipation, abdominal pain and diarrhea. An important gene associated with Celiac Disease 1 is HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1), and among its related pathways/superpathways are Allograft rejection and Cell adhesion molecules. The drugs Prucalopride and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include small intestine to gliadin, small intestine and bone, and related phenotypes are vitamin b12 deficiency and failure to thrive

Disease Ontology : 12 An autoimmune disease of gastrointestinal tract that is caused by a reaction located in small intestine to gliadin, a prolamin (gluten protein) found in wheat, and similar proteins found in the crops of the tribe Triticeae. The disease is associated with HLA-DQ gene. It has symptom abdominal pain, has symptom constipation, has symptom diarrhea, has symptom nausea and vomiting, and has symptom loss of appetite.

GARD : 20 Celiac disease is an autoimmune disorder that damages the small intestine and inhibits absorption of nutrients. People with celiac disease cannot tolerate gluten, a protein in wheat, rye, barley, and in some products such as medicines, vitamins, and lip balms. When affected people eat food with gluten, or use a product with gluten, the immune system reacts by damaging tiny parts of the lining of the small intestine called villi. Because villi normally allow the blood to absorb nutrients from food, affected individuals become malnourished. Classic signs and symptoms are caused by inflammation of the gastrointestinal tract and may include diarrhea, weight loss, abdominal pain, swelling, and food intolerance. However, many people have other symptoms involving many body systems, and some people have no symptoms. While celiac disease tends to run in families, it does not follow a specific inheritance pattern. The risk to develop celiac disease is raised by having certain forms of the HLA-DQA1 and HLA-DQB1 genes. Treatment is a lifelong, gluten-free diet.

OMIM® : 57 Celiac disease, also known as celiac sprue and gluten-sensitive enteropathy (GSE), is a multifactorial disorder of the small intestine that is influenced by both environmental and genetic factors. It is characterized by malabsorption resulting from inflammatory injury to the mucosa of the small intestine after the ingestion of wheat gluten or related rye and barley proteins (summary by Farrell and Kelly, 2002). Long regarded as gastrointestinal disorder of childhood, the disease is now considered to be a chronic systemic autoimmune disease and is more often diagnosed in adults than in children (Monsuur et al., 2005). For a discussion of genetic heterogeneity of celiac disease, see MAPPING. (212750) (Updated 20-May-2021)

MedlinePlus : 42 Celiac disease is an immune disease in which people can't eat gluten because it will damage their small intestine. If you have celiac disease and eat foods with gluten, your immune system responds by damaging the small intestine. Gluten is a protein found in wheat, rye, and barley. It may also be in other products like vitamins and supplements, hair and skin products, toothpastes, and lip balm. Celiac disease affects each person differently. Symptoms may occur in the digestive system, or in other parts of the body. One person might have diarrhea and abdominal pain, while another person may be irritable or depressed. Irritability is one of the most common symptoms in children. Some people have no symptoms. Celiac disease is genetic. Blood tests can help your doctor diagnose the disease. Your doctor may also need to examine a small piece of tissue from your small intestine. Treatment is a diet free of gluten. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

KEGG : 36 Celiac disease is a chronic gluten intolerance that occurs in genetically predisposed individuals. The ingestion of gluten causes chronic inflammation of the small intestinal mucosa, leading to nutrient malabsorption. Susceptibility to celiac disease is strongly associated with particular HLA class II alleles. However, non-HLA genetic factors are likely to be required for the development of the disease. It has been reported that CTLA4 and MYO9B gene polymorphisms are associated with predisposition to celiac disease.

Wikipedia : 73 Coeliac disease or celiac disease is a long-term autoimmune disorder that primarily affects the small... more...

GeneReviews: NBK1727

Related Diseases for Celiac Disease 1

Diseases in the Celiac Disease 1 family:

Celiac Disease 5 Celiac Disease 4
Celiac Disease 2 Celiac Disease 3
Celiac Disease 6 Celiac Disease 7
Celiac Disease 8 Celiac Disease 9
Celiac Disease 10 Celiac Disease 11
Celiac Disease 12 Celiac Disease 13

Diseases related to Celiac Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1162)
# Related Disease Score Top Affiliating Genes
1 refractory celiac disease 33.0 MYO9B IL15 HLA-DQB1
2 autoimmune disease 32.4 TPO TGM2 PTPN22 IL15 HLA-DQB1 HLA-DQA1
3 type 1 diabetes mellitus 32.4 TPO PTPN22 IL15 HLA-DQB1 HLA-DQA1 CTLA4
4 dermatitis herpetiformis 32.3 TGM2 MYO9B HLA-DQB1 HLA-DQA1 CD79A
5 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 32.2 TPO PTPN22 CTLA4
6 immunoglobulin alpha deficiency 32.2 TGM2 HLA-DQB1 CD79A
7 inflammatory bowel disease 32.0 PTPN22 MYO9B IL15 HLA-DQB1 HLA-DQA1 CTLA4
8 thyroiditis 32.0 TPO PTPN22 CTLA4
9 hashimoto thyroiditis 31.8 TPO PTPN22 CTLA4
10 autoimmune hepatitis 31.8 TPO HLA-DQB1 CTLA4
11 microscopic colitis 31.6 TGM2 IL15 HLA-DQB1 CD79A
12 systemic lupus erythematosus 31.5 TPO PTPN22 IL15 HLA-DQB1 HLA-DQA1 CTLA4
13 graves' disease 31.5 TPO PTPN22 HLA-DQB1 HLA-DQA1 CTLA4
14 wheat allergy 31.5 TGM2 HLA-DQB1
15 alopecia areata 31.5 TPO PTPN22 HLA-DQB1 CTLA4
16 lupus erythematosus 31.5 PTPN22 HLA-DQB1 HLA-DQA1 CTLA4
17 juvenile rheumatoid arthritis 31.5 IL15 HLA-DQB1 HLA-DQA1 CTLA4
18 jejunoileitis 31.4 TGM2 MYO9B
19 common variable immunodeficiency 31.3 IL15 HLA-DQB1 CTLA4 CD79A
20 vitiligo-associated multiple autoimmune disease susceptibility 1 31.3 TPO PTPN22 CTLA4
21 immunoglobulin a deficiency 1 31.3 TGM2 CD79A
22 rheumatoid arthritis 31.2 PTPN22 IL15 HLA-DQB1 HLA-DQA1 CTLA4 CD79A
23 multiple sclerosis 31.2 PTPN22 IL15 HLA-DQB1 HLA-DQA1 CTLA4
24 arthritis 31.2 PTPN22 IL15 HLA-DQB1 HLA-DQA1 CTLA4
25 hypoadrenocorticism, familial 30.9 TPO PTPN22 CTLA4
26 lymphopenia 30.8 PTPN22 IL15 CTLA4
27 giardiasis 30.8 TGM2 CD79A
28 myxedema 30.8 TPO CTLA4
29 primary adrenal insufficiency 30.7 HLA-DQB1 HLA-DQA1
30 psoriatic arthritis 30.7 PTPN22 IL15 CTLA4
31 type 1 diabetes mellitus 2 30.6 PTPN22 HLA-DQB1 HLA-DQA1 CTLA4
32 toxoplasmosis 30.5 HLA-DQB1 HLA-DQA1 CD79A
33 guillain-barre syndrome 30.5 HLA-DQB1 HLA-DQA1 CD79A
34 autoimmune hepatitis type 1 30.5 HLA-DQB1 HLA-DQA1
35 type 1 diabetes mellitus 12 30.4 PTPN22 CTLA4
36 central nervous system vasculitis 30.2 PTPN22 CTLA4
37 scleritis 30.1 PTPN22 CTLA4
38 celiac disease 4 11.5
39 celiac disease 3 11.5
40 epilepsy with bilateral occipital calcifications 11.4
41 celiac disease 5 11.4
42 celiac disease 2 11.4
43 celiac disease 6 11.4
44 celiac disease 7 11.4
45 celiac disease 8 11.4
46 celiac disease 9 11.4
47 celiac disease 10 11.4
48 celiac disease 11 11.4
49 celiac disease 12 11.4
50 celiac disease 13 11.4

Comorbidity relations with Celiac Disease 1 via Phenotypic Disease Network (PDN):

Chylomicron Retention Disease Deficiency Anemia
Hypothyroidism Iron Deficiency Anemia
Protein-Energy Malnutrition Tropical Sprue

Graphical network of the top 20 diseases related to Celiac Disease 1:

Diseases related to Celiac Disease 1

Symptoms & Phenotypes for Celiac Disease 1

Human phenotypes related to Celiac Disease 1:

31 (show all 43)
# Description HPO Frequency HPO Source Accession
1 vitamin b12 deficiency 31 occasional (7.5%) HP:0100502
2 failure to thrive 31 HP:0001508
3 depressivity 31 HP:0000716
4 ataxia 31 HP:0001251
5 cerebral calcification 31 HP:0002514
6 short stature 31 HP:0004322
7 delayed puberty 31 HP:0000823
8 vomiting 31 HP:0002013
9 type i diabetes mellitus 31 HP:0100651
10 rickets 31 HP:0002748
11 osteoporosis 31 HP:0000939
12 postnatal growth retardation 31 HP:0008897
13 anxiety 31 HP:0000739
14 elevated hepatic transaminase 31 HP:0002910
15 alopecia 31 HP:0001596
16 celiac disease 31 HP:0002608
17 thyroiditis 31 HP:0100646
18 abdominal pain 31 HP:0002027
19 arthralgia 31 HP:0002829
20 low levels of vitamin d 31 HP:0100512
21 lymphoma 31 HP:0002665
22 hypocalcemia 31 HP:0002901
23 weight loss 31 HP:0001824
24 eczema 31 HP:0000964
25 infertility 31 HP:0000789
26 steatorrhea 31 HP:0002570
27 prolonged prothrombin time 31 HP:0008151
28 diarrhea 31 HP:0002014
29 polyneuropathy 31 HP:0001271
30 abdominal distention 31 HP:0003270
31 recurrent aphthous stomatitis 31 HP:0011107
32 decreased circulating iga level 31 HP:0002720
33 macrocytic anemia 31 HP:0001972
34 low levels of vitamin k 31 HP:0011892
35 hypoplasia of dental enamel 31 HP:0006297
36 abnormality of the abdominal wall 31 HP:0004298
37 thrombocytosis 31 HP:0001894
38 iron deficiency anemia 31 HP:0001891
39 prolonged partial thromboplastin time 31 HP:0003645
40 abnormality of the coagulation cascade 31 HP:0003256
41 stomatitis 31 HP:0010280
42 seizure 31 HP:0001250
43 reduced blood folate concentration 31 HP:0100507

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Neurologic Central Nervous System:
cerebral calcification

Growth Height:
short stature

Neurologic Behavioral Psychiatric Manifestations:

Skeletal Limbs:

Neurologic Peripheral Nervous System:
peripheral neuropathy

Abdomen Gastrointestinal:
recurrent abdominal pain
watery diarrhea (children and adults)
small intestine inflammation
flattened villi
iron deficiency anemia (adults)
macrocytic anemia (folate or rarely b12 deficiency)

iga deficiency

Head And Neck Teeth:
hypoplastic dental enamel

osteoporosis (70% of patients)

Growth Other:
failure to thrive
growth retardation (children)

Endocrine Features:
delayed puberty
type 1 diabetes
autoimmune thyroiditis

Skin Nails Hair Hair:

Laboratory Abnormalities:
prolonged prothrombin time
iiga and igg antigliadin antibodies (aga)
iga antiendomysial antibodies (ema)
anti-tissue transglutaminase antibodies (anti-ttg)
Growth Weight:
weight loss

Head And Neck Mouth:
recurrent aphthous stomatitis

esophageal cancer
intestinal t-cell lymphoma
small bowel cancer
pharyngeal cancer

Skin Nails Hair Skin:
follicular keratosis
dermatitis herpetiformis

Abdomen External Features:
abdominal distention (children)

Clinical features from OMIM®:

212750 (Updated 20-May-2021)


  • constipation
  • abdominal pain
  • diarrhea
  • nausea
  • loss of appetite

UMLS symptoms related to Celiac Disease 1:

nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

Drugs & Therapeutics for Celiac Disease 1

Drugs for Celiac Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Prucalopride Approved Phase 4 179474-81-8
Budesonide Approved Phase 4 51333-22-3 63006 5281004
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
Pancrelipase Approved, Investigational Phase 4 53608-75-6
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
Cobalamin Experimental Phase 4 13408-78-1 6857388
12 Cathartics Phase 4
13 Serotonin Receptor Agonists Phase 4
14 Neurotransmitter Agents Phase 4
15 Laxatives Phase 4
16 Respiratory System Agents Phase 4
17 Anti-Asthmatic Agents Phase 4
18 Hormones Phase 4
19 Hormone Antagonists Phase 4
20 Anti-Inflammatory Agents Phase 4
21 glucocorticoids Phase 4
22 Bronchodilator Agents Phase 4
23 Vitamin B12 Phase 4
24 Vitamin B 6 Phase 4
25 Folate Phase 4
26 Vitamin B Complex Phase 4
27 Acidophilus Phase 4
28 Vitamin B 12 Phase 4
29 Vitamins Phase 4
30 Vitamin B9 Phase 4
31 Bifidobacterium Phase 4
32 Sulfalene Phase 4
33 pancreatin Phase 4
34 Gastrointestinal Agents Phase 4
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
Pyridoxal Experimental, Nutraceutical Phase 4 66-72-8 1050
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
43 Vaccines Phase 3
44 Methylprednisolone Acetate Phase 2, Phase 3
45 Antineoplastic Agents, Hormonal Phase 2, Phase 3
Vedolizumab Approved Phase 2 943609-66-3
Lysine Approved, Nutraceutical Phase 2 56-87-1 5962
Cysteine Approved, Nutraceutical Phase 2 52-90-4 5862
49 Immunoglobulin A Phase 2
50 Cayenne Phase 2

Interventional clinical trials:

(show top 50) (show all 217)
# Name Status NCT ID Phase Drugs
1 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
2 Open-label Withdrawal Trial of Budesonide in Patients With Immune Mediated Enteropathies Recruiting NCT03866538 Phase 4 Withdrawal of Oral Budesonide
3 Celiac Disease and Vitamin Status: Evaluation of the Effect of Supplementation With a Probiotic (VIVOMIXX®) on Vitamin B6, B12, 25'OH D, Folic Acid and Omocystein Levels, Metabolic and Inflammatory Status, and Gut Microbiota Metabolomics in a Cohoort of Celiac Patients Recruiting NCT04160767 Phase 4 Probiotic Vivomixx
4 Does Bowel Preparation (Either as a Single or Divided Dose) Produce Better Cleansing and Diagnostic Yield Than no Preparation at All in Small Bowel Capsule Endoscopy Recruiting NCT03351972 Phase 4 Klean Prep
5 Effect of the Endopeptidase AN-PEP on Gluten Exposure in Real Life in Celiac Disease Patients Treated With a Long-term Gluten-free Diet. Exploratory, Interventional, Prospective, Controlled and Double Blind Study Not yet recruiting NCT04788797 Phase 4 Prolyl Endopeptidase
6 Randomized, Double Blind, Placebo-controlled Trial of Creon in Patients With Low Faecal Pancreatic Elastase Terminated NCT01865695 Phase 4 Creon
7 Pilot Study of the Efficacy of Pancreatic Enzyme Supplementation for Symptom Control in Celiac Disease Not Responding to the Gluten Free Diet Terminated NCT02475369 Phase 4 pancrelipase
8 HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease Completed NCT01100099 Phase 2, Phase 3
9 Effect of Addition of Short Course of Prednisolone to Gluten Free Diet and Gluten Free Diet Alone in the Recovery of Clinical, Histological and Immunological Features in Naive Adult Patients With Celiac Disease Completed NCT01045837 Phase 2, Phase 3 Prednisolone and Gluten free diet
10 Protocol for Correlating Enteropathic Severity and Small Intestinal CYP3A4 Activity in Patients With Celiac Disease Completed NCT01338324 Phase 2, Phase 3 Simvastatin
11 Assessment of the Effect of Gluten Free Toothpaste on the Ulcerative Events in Children With Celiac Disease (Before and After Pilot Study) Completed NCT03771443 Phase 3 experimental gluten free toothpaste
12 Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh Completed NCT01375647 Phase 3
13 A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of Persistent Symptoms in Patients With Celiac Disease on a GFD Recruiting NCT03569007 Phase 3 Larazotide;Matching Placebo
14 Wheat Flour Subjected to Microbial Transglutaminase Enzymatic Treatment in the Presence of Lysine Ethyl Ester for Alimentary Use in the Treatment of Celiac Disease. Unknown status NCT02472119 Phase 2
15 A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease to Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge Unknown status NCT03644069 Phase 2
16 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet Unknown status NCT01917630 Phase 2 ALV003;placebo
17 Combining Necator Americanus With Trace Gluten to Restore Tolerance in Coeliac Disease: a Pilot Clinical and a Detailed in Vitro Immunological Study. Completed NCT01661933 Phase 1, Phase 2
18 Effect of a Cocktail of Two Common Enzyme Supplements on Celiac Disease Patients With Persistent Seropositivity Completed NCT00962182 Phase 1, Phase 2 STAN1;Placebo enzyme;STAN1+gluten
19 Study on The Effectiveness of Oral Administration of Prolyl Endoprotease for Gluten Detoxification as a Means to Treat Coeliac Disease Completed NCT00810654 Phase 1, Phase 2
20 A Phase IIb, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During a Gluten Challenge Completed NCT00889473 Phase 2 Larazotide acetate;Placebo
21 A Double-Blind, Placebo Controlled, Gluten Challenge Trial of the Efficacy, Safety and Tolerability of 6-weeks Treatment of Latiglutenase (IMGX003) Administration in Patients With Well-Controlled Celiac Disease Completed NCT03585478 Phase 2 Latiglutenase
22 A Phase IIb, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During a Gluten Challenge Completed NCT00492960 Phase 2 larazotide acetate;placebo
23 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease, an In Situ Small Bowel T Cell Lymphoma Completed NCT02633020 Phase 2
24 A Phase 2a, Randomized, Double Blinded, Placebo Controlled, Study Evaluating Immunity and Gluten-sensitivity by Inoculating Celiac Disease Patients With the Human Hookworm Necator Americanus. Completed NCT00671138 Phase 2
25 A Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease With Larazotide Acetate (AT-1001) Completed NCT00620451 Phase 2 larazotide acetate;placebo
26 A Phase 2a, Double-Blind, Placebo Controlled Study of the Efficacy, Safety and Tolerability of 6-weeks Treatment With ALV003 In Patients With Well-Controlled Celiac Disease Completed NCT00959114 Phase 2
27 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease Completed NCT02637141 Phase 2
28 A Randomized, Double-blind, Placebo-controlled Study of the Safety, Pharmacodynamics, Efficacy, and Pharmacokinetics of TIMP-GLIA in Subjects With Well-controlled Celiac Disease Undergoing Oral Gluten Challenge Completed NCT03738475 Phase 2 TIMP-GLIA;Placebo
29 A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Different Doses of Larazotide Acetate for the Treatment of Celiac Disease Completed NCT01396213 Phase 2 Larazotide Acetate;placebo
30 A Phase 2a, Double-Blind, Placebo Controlled Study of the Efficacy, Safety and Tolerability of 6-weeks Treatment With Varying Methods of ALV003 Administration in Patients With Well-Controlled Celiac Disease Completed NCT01255696 Phase 2
31 A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease Completed NCT00540657 Phase 2 CCX282-B;Placebo
32 Exploratory, Placebo-controlled Study on the Effects of Bifidobacterium Breve in Children With Celiac Disease Completed NCT02244047 Phase 1, Phase 2 Bifidobacterium breve;Placebo (for Bifidobacterium breve)
33 Phase II Study on Safety of 60 Days Administration of Triticum Monococcum in Patients With Celiac Disease on Remission in Gluten Free Diet Completed NCT02220166 Phase 2
34 A Two-Part, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Systemic Exposure of Single Escalating Administrations and Repeated Administration of BL-7010 in Well-Controlled Celiac Patients Completed NCT01990885 Phase 1, Phase 2 BL-7010;Placebo
35 A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge. Completed NCT00362856 Phase 2 larazotide acetate;Placebo
36 A Randomized Controlled Trial of Dietary Supplementation With Bifidobacterium Infantis NLS Super Strain Among Celiac Disease Patients on a Gluten-free Diet With Persistent Gastrointestinal Symptoms Completed NCT03271138 Phase 2
37 A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study of the Efficacy and Safety of Latiglutenase Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet Recruiting NCT04243551 Phase 2 Latiglutenase
38 A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Persons With Celiac Disease Age > 10 Years Recruiting NCT03707730 Phase 2
39 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients With Non-Responsive Celiac Disease as an Adjunct to a Gluten-free Diet Recruiting NCT04424927 Phase 2
40 A Phase IIa, Double-blind, Randomised, Placebo-controlled Study on the Efficacy and Tolerability of a 14-day Treatment With Teriflunomide vs. Placebo in Subjects With Coeliac Disease Undergoing a 3-day Gluten Challenge Not yet recruiting NCT04806737 Phase 1, Phase 2 Teriflunomide Oral Tablet
41 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-101 for the Prevention of Gluten-Specific T Cell Activation in Subjects With Celiac Disease on a Gluten-Free Diet Not yet recruiting NCT04530123 Phase 2 Placebo;TAK-101
42 Vedolizumab Induction May Prevent Celiac Enteritis After Gluten Challenge in Established Celiac Patients in Histological Remission Terminated NCT02929316 Phase 2 Vedolizumab
43 A Phase 1, Randomized, Double-Blind, Placebo Controlled, Multi-Dose Study to Determine the Safety, Tolerance and Pharmacokinetics of 3 Dose Levels of Larazotide Acetate (AT-1001) in Healthy Volunteers Completed NCT00386490 Phase 1 larazotide acetate
44 Use of an Orally Administered Antibody to Gluten to Prevent the Recurrence of Symptoms and Laboratory Parameters in Persons With Celiac Disease (Gluten Sensitive Enteropathy) Completed NCT01765647 Phase 1
45 Hookworm Therapy for Coeliac Disease: A Phase 1B Safety and Dose-ranging Clinical Trial Examining Sustained Gluten Consumption in Hookworm-naive and Hookworm-infection People With Coeliac Disease Completed NCT02754609 Phase 1
46 A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2 in HLA DQ2+ Volunteers With Coeliac Disease Following a Long-term, Strict Gluten-free Diet Completed NCT00879749 Phase 1
47 A Phase 1, Two Stage, Single-Blind, Single Dose, Placebo Controlled, Dose Escalation, Crossover Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal Completed NCT00669825 Phase 1 ALV003;Placebo
48 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Nexvax2 Preceded by a Dose Titration Period in Subjects With Celiac Disease Currently on a Gluten-Free Diet Completed NCT02528799 Phase 1
49 A Phase 1, First-in-Human, 2-Part, Multicenter Dose Escalation and Repeat Dose Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease Completed NCT03486990 Phase 1 TIMP-GLIA
50 A Phase 1 Study of Nexvax2 Administered Subcutaneously After a Screening Gluten Food Challenge That Compares Relative Bioavailability With Intradermal Administration in Non-homozygous HLA-DQ2.5+ Adults With Celiac Disease Completed NCT03543540 Phase 1

Search NIH Clinical Center for Celiac Disease 1

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Medium chain triglycerides

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Celiac Disease 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Celiac Disease 1:
Regenerative ColoTherapy, stem cells for inflammatory bowel diseases
Embryonic/Adult Cultured Cells Related to Celiac Disease 1:
Adipose-derived mesenchymal stem cells (family)
Peripheral blood-derived hematopoietic stem cells (family)

Cochrane evidence based reviews: celiac disease

Genetic Tests for Celiac Disease 1

Genetic tests related to Celiac Disease 1:

# Genetic test Affiliating Genes
1 Celiac Disease 29
2 Celiac Disease, Susceptibility to 29

Anatomical Context for Celiac Disease 1

The Foundational Model of Anatomy Ontology organs/tissues related to Celiac Disease 1:

Small Intestine To Gliadin

MalaCards organs/tissues related to Celiac Disease 1:

Small Intestine, Bone, Liver, Thyroid, T Cells, Skin, Heart

Publications for Celiac Disease 1

Articles related to Celiac Disease 1:

(show top 50) (show all 12430)
# Title Authors PMID Year
A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. 25 57 61
15357948 2004
Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. 57 61 54
16282976 2005
Identification of tissue transglutaminase as the autoantigen of celiac disease. 57 54 61
9212111 1997
Evolutionary and functional analysis of celiac risk loci reveals SH2B3 as a protective factor against bacterial infection. 61 57
20560212 2010
Newly identified genetic risk variants for celiac disease related to the immune response. 61 57
18311140 2008
A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. 61 57
17558408 2007
The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. 57 61
15825128 2005
Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. 57 61
15357947 2004
Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. 57 61
15020763 2004
The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. 61 57
14530392 2003
Celiac disease--the villain unmasked? 57 61
12815145 2003
Celiac disease--how to handle a clinical chameleon. 61 57
12815143 2003
Prevalence of Celiac disease among children in Finland. 57 61
12815137 2003
Celiac disease association with CD8+ T cell responses: identification of a novel gliadin-derived HLA-A2-restricted epitope. 57 61
12594302 2003
Structural basis for gluten intolerance in celiac sprue. 54 57
12351792 2002
Genome-wide linkage analysis for celiac disease in North American families. 57 61
12124726 2002
Genomewide linkage analysis of celiac disease in Finnish families. 57 61
11715113 2002
Genome-wide linkage analysis of Scandinavian affected sib-pairs supports presence of susceptibility loci for celiac disease on chromosomes 5 and 11. 61 57
11840196 2001
Use of closely related affected individuals for the genetic study of complex diseases in founder populations. 57 61
11102286 2001
Concordance of dermatitis herpetiformis and celiac disease in monozygous twins. 57 61
11121131 2000
Transglutaminase antibodies in children with a genetic risk for celiac disease. 57 61
10969260 2000
The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. 61 57
10684852 2000
The prevalence of celiac disease in at-risk groups of children in the United States. 61 57
10636980 2000
Genetic susceptibility to gluten sensitive enteropathy in Irish setter dogs is not linked to the major histocompatibility complex. 57 61
9894853 1998
Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. 57 61
9623982 1998
Celiac disease risk in the USA: high prevalence of antiendomysium antibodies in healthy blood donors. 57 61
9648988 1998
An autosomal screen for genes that predispose to celiac disease in the western counties of Ireland. 61 57
8896565 1996
HLA susceptibility genes in celiac disease: genetic mapping and role in pathogenesis. 61 57
8359659 1993
Incidence of celiac disease identified by the presence of serum endomysial antibodies in children with chronic diarrhea, short stature, or insulin-dependent diabetes mellitus. 61 57
8345423 1993
Extended major histocompatibility complex haplotypes in celiac patients in the west of Ireland. 61 57
8434627 1993
An extended HLA-D region haplotype associated with celiac disease. 57 61
2893373 1988
Human leukocyte antigen (HLA)-DQ2 and -DQ8 haplotypes in celiac, celiac with type 1 diabetic, and celiac suspected pediatric cases. 61 42
33725967 2021
Gliadin Sequestration as a Novel Therapy for Celiac Disease: A Prospective Application for Polyphenols. 42 61
33435615 2021
Celiac disease and COVID-19 pandemic: should we worry? 42 61
33321006 2020
IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease. 57
32051586 2020
Pathogenesis of Enteropathy-Associated T Cell Lymphoma. 25 61
29943210 2018
Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity. 25 61
29102613 2018
Prevalence of Celiac Disease in Patients with Autoimmune Thyroid Disease: A Meta-Analysis. 61 25
27256300 2016
Features and Progression of Potential Celiac Disease in Adults. 61 25
26538207 2016
Celiac disease and non-celiac gluten sensitivity. 61 25
26438584 2015
The present and the future in the diagnosis and management of celiac disease. 25 61
25326000 2015
Introduction of gluten, HLA status, and the risk of celiac disease in children. 61 25
25271602 2014
Risk of pediatric celiac disease according to HLA haplotype and country. 25 61
24988556 2014
ACG clinical guidelines: diagnosis and management of celiac disease. 25 61
23609613 2013
Review article: coeliac disease, new approaches to therapy. 61 25
22324389 2012
Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity. 61 25
21392369 2011
Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. 57
21307853 2011
Risk factors in familial forms of celiac disease. 61 25
20397258 2010
Stratifying risk for celiac disease in a large at-risk United States population by using HLA alleles. 61 25
19500688 2009
HLA-DQ and risk gradient for celiac disease. 25 61
19027045 2009

Variations for Celiac Disease 1

Expression for Celiac Disease 1

Search GEO for disease gene expression data for Celiac Disease 1.

Pathways for Celiac Disease 1

GO Terms for Celiac Disease 1

Cellular components related to Celiac Disease 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II protein complex GO:0042613 8.62 HLA-DQB1 HLA-DQA1

Biological processes related to Celiac Disease 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 8.96 HLA-DQB1 HLA-DQA1
2 T cell receptor signaling pathway GO:0050852 8.92 PTPN22 HLA-DQB1 HLA-DQA1 CTLA4

Molecular functions related to Celiac Disease 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 8.62 HLA-DQB1 HLA-DQA1

Sources for Celiac Disease 1

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....